If you or a loved one has been prescribed Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection has been documented in patients using the drug, and understanding the reported patterns is essential. Building on decades of pharmacovigilance research, this page provides a concise overview of what current medical reports say about Tysabri-associated PML.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus and typically occurs only in immunocompromised patients. Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment and understanding of the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also notes that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML presents with progressive neurological deficits, including cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The condition often leads to severe disability or death, as emphasized in the boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early recognition is crucial for potential treatment and for legal purposes, as the statute of limitations may depend on when the injury was discovered.
Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus, allowing reactivation and spread of the virus in the brain. The resulting lytic infection of oligodendrocytes leads to demyelination and the clinical syndrome of PML. Understanding this mechanism is important for establishing causation in legal claims.
The boxed warning explicitly states that Tysabri increases PML risk and identifies the three key risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether patients and healthcare providers were adequately informed about the magnitude of risk, the importance of anti-JCV antibody testing, and the need for vigilant monitoring. The TOUCH program aims to ensure informed consent, but some patients may not have fully understood the potential for severe outcomes.
For Virginia residents who developed PML after Tysabri treatment, legal claims may involve product liability, failure to warn, or negligence. The statute of limitations for personal injury claims in Virginia is generally two years from the date of injury or from when the injury was discovered (or reasonably should have been discovered). For PML, the timeline between Tysabri exposure and documented harm can vary. PML may develop months to years after starting treatment, and symptoms can be subtle initially. The statute of limitations clock typically starts when the patient knew or should have known that PML was caused by Tysabri. Given the severity of PML, early consultation with an attorney is advisable to preserve legal rights.
The label notes that PML risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported after shorter exposure. The latency period from JC virus reactivation to clinical symptoms can be weeks to months. Once symptoms appear, diagnosis may be delayed if PML is not suspected. This delay can affect the statute of limitations, as the injury may not be immediately linked to Tysabri.
Tysabri carries a known risk of PML, a devastating brain infection. Patients in Virginia who have been harmed should be aware of the medical evidence linking Tysabri to PML, the importance of timely diagnosis, and the legal time limits for filing claims. Consulting with an attorney experienced in pharmaceutical litigation is essential to navigate the statute of limitations and assess the adequacy of warnings provided.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Virginia, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered (or reasonably should have been discovered). For PML, the clock typically starts when the patient knew or should have known that PML was caused by Tysabri. Given the variable latency and diagnostic delays, early legal consultation is critical.
The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, a severe brain infection caused by the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Risk factors include anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior immunosuppressant use.
PML diagnosis involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. Symptoms include progressive neurological deficits such as cognitive impairment, motor weakness, and visual disturbances.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.